Aclaris Therapeutics’ (ACRS) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a report issued on Tuesday, Benzinga reports.

Separately, StockNews.com raised shares of Aclaris Therapeutics from a sell rating to a hold rating in a report on Thursday, July 25th. Seven research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Hold and a consensus price target of $23.00.

Aclaris Therapeutics Price Performance

ACRS opened at $1.21 on Tuesday. The company has a market capitalization of $86.23 million, a price-to-earnings ratio of -1.11 and a beta of 0.21. The firm’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.21. Aclaris Therapeutics has a 1 year low of $0.59 and a 1 year high of $7.47.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. The firm had revenue of $2.77 million for the quarter, compared to the consensus estimate of $1.74 million. Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%. As a group, equities analysts anticipate that Aclaris Therapeutics will post -0.65 EPS for the current year.

Insider Transactions at Aclaris Therapeutics

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard bought 173,730 shares of the stock in a transaction dated Tuesday, July 30th. The shares were bought at an average cost of $1.30 per share, for a total transaction of $225,849.00. Following the purchase, the insider now directly owns 13,776,421 shares of the company’s stock, valued at approximately $17,909,347.30. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have acquired 930,502 shares of company stock worth $1,119,232 in the last ninety days. Company insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Aclaris Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in Aclaris Therapeutics in the 1st quarter valued at about $39,000. SG Americas Securities LLC raised its stake in Aclaris Therapeutics by 69.5% in the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 13,461 shares during the period. Russell Investments Group Ltd. raised its stake in Aclaris Therapeutics by 5,265.1% in the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 61,602 shares during the period. Deuterium Capital Management LLC bought a new stake in Aclaris Therapeutics in the 1st quarter valued at about $99,000. Finally, Marquette Asset Management LLC bought a new stake in Aclaris Therapeutics in the 1st quarter valued at about $104,000. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.